AbbVie Inc.

Good morning and thank you for standing by. Welcome to the AbbVie second quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question and answer portion of this call. You may ask a question by pressing star 1 on your phone. I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations.

Good morning and thanks for joining us. Also on the call with me today are Rob Michael, Chief Executive Officer, Jeff Stewart, Executive Vice President, Chief Commercial Officer, Rupal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer, Scott Renz, Executive Vice President, Chief Financial Officer, and Kerry Strom, Senior Vice President, AbbVie, and President, Global Allergan Aesthetics. Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. Abbey undertakes no obligation to update these forward-looking statements except as required by law. On today's conference call, non-GAAP financial measures will be used to help investors understand Abbey's business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we'll take your questions. So with that, I'll turn the call over to Rob.

Thank you, Liz. Good morning, everyone, and thank you for joining us. It's a pleasure to speak with you today as Abby's new CEO. I look forward to building on our track record of success and delivering on Abby's promise to our patients, employees, shareholders, and communities. As we begin this new chapter, nearly every aspect of Abby's business is performing at, or above our expectations. We are demonstrating a rapid return to revenue growth, with operational sales up nearly 4% through the first half of this year, including robust mid-single-digit growth in the second quarter. Our exumeric growth platform, which covers more than 80% of AbbVie's total sales, will outperform our initial full-year sales guidance by more than $1 billion. driven by strong performance in immunology and oncology. In addition, US Humira performance continues to meet our expectations, having achieved or exceeded our guidance in all six quarters with biosimilar competition. The strong performance across our diversified portfolio will drive top-tier, high single-digit compound growth through the end of this decade. which will support continued investment to drive growth in the next decade. Turning to our results, I'm especially pleased with Immunology, where our leading portfolio is delivering performance well above our expectations. Guy Rizzi continues to demonstrate strong momentum in psoriasis and Crohn's disease, where we have substantial headroom for additional share gains. and the recent approval in UC will add another source of long-term growth. Renvoke is also delivering robust growth across all approved indications. We are making excellent progress with late-stage development in five additional indications that we anticipate will launch in the second half of this decade. In oncology, Elihir has accelerated our on-market presence in solid tumors. We also have several exciting pipeline programs, including two novel CMET ADCs for solid tumors, Teliso-V and 400, as well as 383, our BCMA-CD3 bispecific for multiple myeloma. In neuroscience, our leading therapies for migraine and mood disorders continue to gain share and are competitively well-positioned. The pending acquisition of Cereval will further augment our neuroscience pipeline, and we're excited about what our two companies can achieve together to make a difference for patients with neuropsych disorders. We have certified substantial compliance to the FTC second request and anticipate the Cereval transaction will close soon. Lastly, we've been very active with business development. investing in exciting opportunities that can drive growth in the next decade. Through the first half of this year, we have executed nearly a dozen early stage deals. These include promising technologies and innovative mechanisms that can elevate the standard of care in immunology, oncology, and neuroscience. In summary, I'm very pleased with the strong momentum of our business. AbbVie's results once again exceed our expectations, and we are raising guidance for the second time this year, underscoring our confidence in the business. The robust performance of our growth platform and the advancement of our pipeline supports AbbVie's top-tier long-term outlook. With that, I'll turn the call over to Jeff for additional comments on our commercial highlights. Jeff?